12月3日，陇神戎发盘中上涨2.18%，截至13:08，报10.79元/股，成交1.77亿元，换手率5.49%，总市值 32.73亿元。 资金流向方面，主力资金净流入709.74万元，特大单买入0.00元，占比0.00%，卖出328.19万元，占比 1.86%；大单买入4162.69万元，占比23.54%，卖出3124.76万元，占比17.67%。 陇神戎发所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中药、医药电商、小盘、甘 肃国资、医疗器械等。 截至11月28日，陇神戎发股东户数2.78万，较上期增加3.93%；人均流通股10874股，较上期减少 3.78%。2025年1月-9月，陇神戎发实现营业收入6.47亿元，同比减少19.71%；归母净利润2702.94万元， 同比增长9.13%。 分红方面，陇神戎发A股上市后累计派现4264.16万元。近三年，累计派现2426.76万元。 机构持仓方面，截止2025年9月30日，陇神戎发十大流通股东中，汇添富中证中药ETF（560080）位居 第五大流通股东，持股133.03万股，相比上期增加35.18万股。 责任编辑：小浪快报 陇神戎发今年以来股价 ...

（文章来源：证券日报） 证券日报网讯 11月28日晚间，陇神戎发发布公告称，公司于2025年11月28日获得由国家药品监督管理 局颁发的《中华人民共和国医疗器械注册证》，产品名称：血液透析浓缩液。 ...

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

截至发稿，陇神戎发市值为31亿元。 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 （记者 曾健辉） 每经AI快讯，陇神戎发（SZ 300534，收盘价：10.32元）11月28日晚间发布公告称，甘肃陇神戎发药业 股份有限公司于2025年11月28日获得由国家药品监督管理局颁发的《中华人民共和国医疗器械注册 证》。产品名称为"血液透析浓缩液"。 2025年1至6月份，陇神戎发的营业收入构成为：药品销售占比86.53%，医疗器械销售占比6.69%，物流 配送占比4.48%，房屋租赁占比0.76%，提供咨询占比0.7%。 ...

智通财经APP讯，陇神戎发(300534.SZ)发布公告，公司于2025年11月28日获得由国家药品监督管理局颁 发的血液透析浓缩液《中华人民共和国医疗器械注册证》。 血液透析浓缩液由A浓缩液和B浓缩液两部分组成。A浓缩液由氯化钠(NaCl)、氯化钾(KCl)、氯化钙 (CaCl2·2H2O)、氯化镁(MgCl2·6H2O)、冰醋酸(CH3COOH)及透析用水组成，B浓缩液由碳酸氢钠 (NaHCO3)和透析用水组成。适用范围：用于急性肾衰竭、慢性肾衰竭的血液透析治疗。 ...

Core Viewpoint - The company, Longshen Rongfa, has received a medical device registration certificate for its blood dialysis concentrate from the National Medical Products Administration, indicating a significant regulatory milestone for its product line [1] Group 1: Product Details - The blood dialysis concentrate consists of two parts: A concentrate and B concentrate [1] - A concentrate includes sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2.2H2O), magnesium chloride (MgCl2.6H2O), acetic acid (CH3COOH), and dialysis water [1] - B concentrate is composed of sodium bicarbonate (NaHCO3) and dialysis water [1] Group 2: Application Scope - The product is intended for use in the treatment of acute renal failure and chronic renal failure through blood dialysis [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-079 甘肃陇神戎发药业股份有限公司 关于获得血液透析浓缩液医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 注册人名称：甘肃陇神戎发药业股份有限公司 注册人住所及生产地址：甘肃省兰州市榆中县定远镇国防路 10 号 产品名称：血液透析浓缩液 型号、规格： | 型号 | 组成 | 规格 | 装量 | | --- | --- | --- | --- | | LS-Y1 | A 浓缩液 | A1 | 5L | | | | A2 | 10L | | | B 浓缩液 | B1 | 6L | | | | B2 | 12L | 结构及组成：血液透析浓缩液由 A 浓缩液和 B 浓缩液两部分组成。A 浓缩液 由氯化钠（NaCl）、氯化钾（KCl）、氯化钙（CaCl2·2H2O）、氯化镁（MgCl2·6H2O）、 冰醋酸（CH3COOH）及透析用水组成，B 浓缩液由碳酸氢钠（NaHCO3）和透析用 水组成。 适用范围：用于急性肾衰竭、慢性肾衰竭的血液透析治疗。 生效日期：二〇二五年十一月二十八日 ...

证券日报网讯 11月20日晚间，陇神戎发发布公告称，公司控股子公司甘肃普安制药股份有限公司因 《药品生产许可证》有效期即将届满而提前办理了换证手续，于近日收到由甘肃省药品监督管理局核准 换发的《药品生产许可证》。 （编辑 楚丽君） ...

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-078 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品生产许可证》的公告 企业负责人：王明宏 质量负责人：陈双明 生产地址和生产范围：甘肃省武威市凉州区黄羊生态工业（食品）示范园农 大北路 1 号：合剂，膜剂，原料药（盐酸纳洛酮），前处理、提取*** 有效期至：2030 年 11 月 13 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）因《药品生产许可证》有效期即将 届满而提前办理了换证手续，于近日收到由甘肃省药品监督管理局核准换发的 《药品生产许可证》，现将有关情况公告如下： 一、换发后的《药品生产许可证》基本信息 企业名称：甘肃普安制药股份有限公司 社会信用代码：91620600762352467T 注册地址：甘肃省武威市凉州区黄羊生态工业（食品）示范园农大北路 1 号 法定代表人：王明宏 特此公告。 甘肃陇神戎发药业股份有限公司董事会 许可证编号：甘 201600 ...